GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Piotroski F-Score

ATRA (Atara Biotherapeutics) Piotroski F-Score : 3 (As of Jul. 15, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Atara Biotherapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Atara Biotherapeutics's Piotroski F-Score or its related term are showing as below:

ATRA' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 3

During the past 13 years, the highest Piotroski F-Score of Atara Biotherapeutics was 5. The lowest was 1. And the median was 3.


Atara Biotherapeutics Piotroski F-Score Historical Data

The historical data trend for Atara Biotherapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Piotroski F-Score Chart

Atara Biotherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 4.00 3.00 1.00 4.00

Atara Biotherapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 3.00 4.00 4.00 3.00

Competitive Comparison of Atara Biotherapeutics's Piotroski F-Score

For the Biotechnology subindustry, Atara Biotherapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was -19.049 + -21.909 + -12.693 + 38.01 = $-15.6 Mil.
Cash Flow from Operations was -10.645 + -3.989 + -24.471 + -28.138 = $-67.2 Mil.
Revenue was 28.64 + 40.19 + 32.753 + 98.149 = $199.7 Mil.
Gross Profit was 24.013 + 32.588 + 25.958 + 77.71 = $160.3 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was
(165.272 + 117.284 + 142.706 + 109.098 + 62.038) / 5 = $119.2796 Mil.
Total Assets at the begining of this year (Mar24) was $165.3 Mil.
Long-Term Debt & Capital Lease Obligation was $26.7 Mil.
Total Current Assets was $27.2 Mil.
Total Current Liabilities was $47.9 Mil.
Net Income was -71.108 + -69.797 + -60.45 + -31.752 = $-233.1 Mil.

Revenue was 0.957 + 2.138 + 4.252 + 27.357 = $34.7 Mil.
Gross Profit was -1.938 + -0.477 + 1.092 + 25.372 = $24.0 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was
(302.083 + 246.439 + 188.788 + 165.504 + 165.272) / 5 = $213.6172 Mil.
Total Assets at the begining of last year (Mar23) was $302.1 Mil.
Long-Term Debt & Capital Lease Obligation was $42.2 Mil.
Total Current Assets was $106.4 Mil.
Total Current Liabilities was $180.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Atara Biotherapeutics's current Net Income (TTM) was -15.6. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Atara Biotherapeutics's current Cash Flow from Operations (TTM) was -67.2. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=-15.641/165.272
=-0.09463793

ROA (Last Year)=Net Income/Total Assets (Mar23)
=-233.107/302.083
=-0.7716654

Atara Biotherapeutics's return on assets of this year was -0.09463793. Atara Biotherapeutics's return on assets of last year was -0.7716654. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Atara Biotherapeutics's current Net Income (TTM) was -15.6. Atara Biotherapeutics's current Cash Flow from Operations (TTM) was -67.2. ==> -67.2 <= -15.6 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=26.708/119.2796
=0.22391088

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=42.197/213.6172
=0.19753559

Atara Biotherapeutics's gearing of this year was 0.22391088. Atara Biotherapeutics's gearing of last year was 0.19753559. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=27.182/47.892
=0.5675687

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=106.434/180.69
=0.58904201

Atara Biotherapeutics's current ratio of this year was 0.5675687. Atara Biotherapeutics's current ratio of last year was 0.58904201. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Atara Biotherapeutics's number of shares in issue this year was 10.851. Atara Biotherapeutics's number of shares in issue last year was 5.623. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=160.269/199.732
=0.80242024

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=24.049/34.704
=0.69297487

Atara Biotherapeutics's gross margin of this year was 0.80242024. Atara Biotherapeutics's gross margin of last year was 0.69297487. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=199.732/165.272
=1.20850477

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=34.704/302.083
=0.11488233

Atara Biotherapeutics's asset turnover of this year was 1.20850477. Atara Biotherapeutics's asset turnover of last year was 0.11488233. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Atara Biotherapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Atara Biotherapeutics  (NAS:ATRA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Atara Biotherapeutics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics Business Description

Traded in Other Exchanges
Address
1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Executives
Anhco Nguyen officer: EVP, Chief Sci. & Tech Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Jill Henrich officer: EVP, Global Head RA & Quality 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Eric J Hyllengren officer: SVP, CFO 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Amar Murugan officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Pascal Touchon director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Manher Joshi officer: EVP, Chief Medical Officer 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard officer: EVP, Chief Technical Officer C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell officer: Chief Tech. Operations Officer C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080